What is Alembic Pharmaceuticals Ltd's PE ratio?

Alembic Pharmaceuticals Ltd trades at a P/E ratio of 22.90.

What is Alembic Pharmaceuticals Ltd's market cap?

Alembic Pharmaceuticals Ltd's market capitalisation is ₹16,712 Cr.

When are Alembic Pharmaceuticals Ltd's next results?

Alembic Pharmaceuticals Ltd's next earnings date is 4 Aug '26.

What is Alembic Pharmaceuticals Ltd's ROE?

Alembic Pharmaceuticals Ltd's return on equity (ROE) is 13.4%.

What sector is Alembic Pharmaceuticals Ltd in?

Alembic Pharmaceuticals Ltd (APLLTD) is classified in the Healthcare sector (Pharmaceuticals).

Healthcare · Pharmaceuticals

Alembic Pharmaceuticals Ltd (APLLTD)

₹797.60

Mkt cap

₹16,712 Cr

P/E ratio

22.90

P/B

2.76

Div yield

1.41%

ROE

13.40%

ROCE

12.60%

EPS (TTM)

₹34.83

Book value

₹289

52W range

647–1,031

Sector

Healthcare

Alembic Pharmaceuticals is in the business of development, manufacturing, and marketing of Pharmaceuticals products i.e. Formulations and Active Pharmaceutical Ingredients. The company has 3 R&D and 5 manufacturing facilities.

NSE APLLTDBSE 533573www.alembic-india.com

Health check

Mixed

ValuationCheap

ProfitabilityAverage

GrowthModerate

TechnicalsBearish

52-week range

−22.67% from high

₹798

₹647+23.36% from low₹1,031

Current

₹797.60

Prev close

₹798.00

Day

−0.05%

Price performance

−0.05%

−5.35%

+3.38%

+6.20%

+4.24%

−23.01%

YTD

−4.48%

Financials

F

Revenue, profit & margin

P/E ratio

22.9×

APLLTD is 34% below the sector median of 34.9×

APLLTD22.9×

Sector median34.9×

	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026
Sales	1,406	1,486	1,595	1,631	1,517	1,562	1,648	1,693	1,770	1,711	1,910	1,876	1,848
Expenses	1,203	1,287	1,387	1,364	1,257	1,325	1,409	1,433	1,498	1,430	1,594	1,585	1,620
Operating Profit	204	199	208	266	260	237	239	260	271	281	316	292	228
OPM %	14%	13%	13%	16%	17%	15%	15%	15%	15%	16%	17%	16%	12%
Other Income	1	12	10	3	4	2	30	10	14	6	8	-27	2
Interest	14	14	16	15	11	13	19	22	25	24	24	23	23
Depreciation	74	66	68	69	69	69	71	70	69	74	76	80	89
Profit before tax	116	130	135	185	183	157	180	178	192	190	224	162	119
Tax %	-31%	7%	-1%	2%	3%	14%	15%	23%	18%	19%	18%	18%	-70%
Net Profit	153	121	137	180	178	135	153	138	157	154	184	132	202
EPS in Rs	7.76	6.14	6.95	9.18	9.07	6.85	7.80	7.04	7.98	7.85	9.40	6.76	10.31
Raw PDF

Earnings

EResults dates & reactions

Next results

4 Aug '26scheduled

Fresh quarters land in the Financials table above, tagged NSE until screener catches up.

Avg earnings-day move −0.95% · closed higher next day 17 of last 56

	Q1FY24	Q2FY24	Q3FY24	Q4FY24	Q1FY25	Q2FY25	Q3FY25	Q4FY25†	Q1FY26	Q2FY26	Q3FY26	Q4FY26
Broadcast	4 Aug '23◦	7 Nov '23◦	5 Feb '24◦	9 May '24◦	8 Aug '24◦	7 Nov '24◦	3 Feb '25◦	12 May '25	5 Aug '25◦	4 Nov '25	5 Feb '26	15 May '26
Earnings day	+1.65%	−0.97%	+2.15%	−2.57%	−6.89%	−3.86%	−2.88%	−2.35%	+0.18%	+3.95%	+1.52%	−0.20%
+1 day	+1.36%	−0.78%	+1.23%	−4.80%	−8.50%	−4.43%	−2.06%	−0.56%	+0.41%	−0.96%	−0.09%	−7.80%
+5 days	+1.31%	+0.65%	+2.95%	−4.14%	−11.78%	−5.12%	−4.35%	+14.20%	−0.40%	−0.82%	−1.06%	−3.82%
+15 days	−1.70%	+1.51%	+8.83%	−7.81%	−11.87%	+1.80%	−12.73%	+10.57%	−1.01%	−1.02%	−8.61%	−5.12%
+30 days	−0.52%	+4.49%	−2.04%	−9.87%	−4.02%	−4.12%	−8.00%	+4.31%	+1.32%	−8.34%	−15.16%	+4.72%
Filing	XBRL	XBRL	XBRL	XBRL	XBRL	XBRL	XBRL	XBRL	XBRL	PDF	XBRL	XBRL

Corporate actions

CLast 6 months

Kind	Value	Ex-date	Record
dividend Dividend - Rs 12 Per Share	12.00	29 Jul '26	29 Jul '26

Shareholding

Sas of Mar 2026

69.74%Promoter

Promoters69.74%

FIIs4.26%0.03

DIIs16.17%

Public9.83%

Ownership trend

Peers

P8 companies

Valuation vs quality

P/E × ROCE · bubble = market cap

Name	CMP	P/E	Mkt Cap	Div Yld	NP Qtr	Qtr Profit Var	Sales Qtr	Qtr Sales Var	ROCE
Sun Pharma.Inds.	₹1,951.50	37.73	4,68,821	0.82%	2,710	+13.58%	14,612	+12.76%	20.53%
Divi's Lab.	₹7,273.00	73.64	1,93,164	0.41%	751	+13.44%	2,831	+9.52%	21.96%
Torrent Pharma.	₹5,017.80	77.52	1,69,902	0.76%	364	−20.58%	4,197	+41.84%	15.19%
Cipla	₹1,438.00	30.51	1,16,132	0.90%	543	−54.61%	6,541	−2.80%	15.49%
Zydus Lifesci.	₹1,156.90	21.26	1,15,376	0.09%	1,341	+21.92%	7,587	+16.22%	21.14%
Lupin	₹2,493.00	20.04	1,13,977	0.72%	1,469	+101.49%	7,475	+31.89%	29.93%
Mankind Pharma	₹2,543.10	52.29	1,05,054	0.04%	559	+34.23%	3,443	+11.81%	13.50%
Alembic Pharma	₹850.05	22.87	16,712	1.41%	202	+40.82%	1,848	+4.41%	12.64%
Median: 156 Co.	₹434.68	34.89	2,013	0.08%	12	+22.43%	177	+16.46%	15.19%

Filings

D

Annual reports15

Financial Year 2026bse Financial Year 2025bse Financial Year 2024bse Financial Year 2023bse Financial Year 2022bse Financial Year 2021bse Financial Year 2020bse Financial Year 2019bse Financial Year 2018bse Financial Year 2017bse Financial Year 2016bse Financial Year 2015bse Financial Year 2014bse Financial Year 2013bse Financial Year 2012bse

Credit ratings6

Rating update 30 Juncrisil Rating update 11 Juncare Rating update 25 Jul 2025crisil Rating update 12 Jun 2025crisil Rating update 12 Jun 2025care Rating update 25 Feb 2025crisil

Announcements5

Disclosure Under Regulation 30 Of SEBI (LODR) Regulations, 2015. 2d - USFDA issued July 10, 2026 warning letter to clinical investigator; no data integrity issue or facility restriction.Announcement under Regulation 30 (LODR)-Newspaper Publication 11 Jul - The copy of the Newspaper Publication published on 11th July, 2026.Specimen Copy Of The Letter Sent To The Shareholders Under Regulation 36(1)(B) Of SEBI LODR 10 Jul - 16th AGM on 5 August 2026; final dividend record date 29 July 2026, payment6 August.Intimation Of Record Date For Payment Of Dividend On Equity Shares For The Financial Year Ended 31St March, 2026. 10 Jul Business Responsibility and Sustainability Reporting (BRSR) 10 Jul - Submitted FY26 BRSR with Bureau Veritas reasonable assurance on July 10, 2026.